United Therapeutics (NASDAQ:UTHR) Downgraded by StockNews.com to Buy

StockNews.com downgraded shares of United Therapeutics (NASDAQ:UTHRFree Report) from a strong-buy rating to a buy rating in a report published on Tuesday morning.

Other equities analysts have also issued research reports about the company. SVB Leerink started coverage on United Therapeutics in a research note on Monday, February 5th. They set an outperform rating and a $330.00 price objective on the stock. HC Wainwright reissued a buy rating and set a $300.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. The Goldman Sachs Group raised United Therapeutics from a sell rating to a neutral rating and boosted their price objective for the stock from $213.00 to $215.00 in a research note on Monday, February 12th. Wedbush reissued an outperform rating and set a $308.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. Finally, Wells Fargo & Company boosted their price objective on United Therapeutics from $309.00 to $325.00 and gave the stock an overweight rating in a research note on Thursday, March 7th. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus price target of $294.40.

View Our Latest Report on United Therapeutics

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $247.86 on Tuesday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.41 and a quick ratio of 4.28. The business’s 50 day moving average price is $225.13 and its 200-day moving average price is $227.28. The firm has a market capitalization of $11.66 billion, a PE ratio of 12.49 and a beta of 0.52. United Therapeutics has a 1 year low of $204.44 and a 1 year high of $261.54.

United Therapeutics (NASDAQ:UTHRGet Free Report) last issued its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.28 by $0.08. The firm had revenue of $614.70 million for the quarter, compared to analyst estimates of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The business’s revenue was up 25.1% on a year-over-year basis. During the same period in the previous year, the company posted $2.67 earnings per share. As a group, equities research analysts expect that United Therapeutics will post 23.32 earnings per share for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 15,000 shares of the business’s stock in a transaction on Friday, March 22nd. The stock was sold at an average price of $237.05, for a total value of $3,555,750.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $30,816.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, CEO Martine A. Rothblatt sold 15,000 shares of the business’s stock in a transaction on Friday, March 22nd. The stock was sold at an average price of $237.05, for a total value of $3,555,750.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $30,816.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Paul A. Mahon sold 6,000 shares of the business’s stock in a transaction on Thursday, March 21st. The shares were sold at an average price of $236.45, for a total value of $1,418,700.00. Following the completion of the sale, the executive vice president now owns 36,710 shares in the company, valued at approximately $8,680,079.50. The disclosure for this sale can be found here. Insiders have sold 61,680 shares of company stock worth $14,161,680 over the last quarter. 12.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On United Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of UTHR. Great West Life Assurance Co. Can increased its holdings in United Therapeutics by 8.9% during the 1st quarter. Great West Life Assurance Co. Can now owns 28,326 shares of the biotechnology company’s stock worth $5,244,000 after purchasing an additional 2,320 shares during the period. Canada Pension Plan Investment Board increased its holdings in United Therapeutics by 229.6% during the 1st quarter. Canada Pension Plan Investment Board now owns 2,063 shares of the biotechnology company’s stock worth $371,000 after purchasing an additional 1,437 shares during the period. Prudential PLC purchased a new stake in United Therapeutics during the 1st quarter worth about $1,160,000. Zions Bancorporation N.A. purchased a new stake in United Therapeutics during the 1st quarter worth about $66,000. Finally, Covestor Ltd increased its holdings in United Therapeutics by 187.5% during the 1st quarter. Covestor Ltd now owns 877 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 572 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Further Reading

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.